{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:48:36Z","timestamp":1792522116328,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.radonc.2020.12.015","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T03:25:43Z","timestamp":1608089143000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) \u2013 An analysis of UK\u2019s largest cohort of lung SABR patients"],"prefix":"10.1016","volume":"156","author":[{"given":"Animesh","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-4215","authenticated-orcid":false,"given":"Matthew","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-8380","authenticated-orcid":false,"given":"Nathaniel","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-8026","authenticated-orcid":false,"given":"Pooja","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.12.015_b0005","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/annonc\/mdu089","article-title":"2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up","volume":"25","author":"Vansteenkiste","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.thorsurg.2014.12.003","article-title":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening","volume":"25","author":"Wood","year":"2015","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.radonc.2020.12.015_b0015","unstructured":"Lung cancer diagnosis and management 2019 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng122\/chapter\/Recommendations#treatment."},{"key":"10.1016\/j.radonc.2020.12.015_b0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2020.12.015_b0025","first-page":"42","article-title":"Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?","volume":"4","author":"Mirimanoff","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2009.12.008","article-title":"Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications","volume":"94","author":"Chi","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0360-3016(03)00095-6","article-title":"Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers","volume":"56","author":"Onimaru","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jjco\/hyt014","article-title":"Stereotactic body radiation therapy for stage I non-small-cell lung cancer: a historical overview of clinical studies","volume":"43","author":"Onishi","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1748-717X-2-21","article-title":"Exceptionally high incidence of symptomatic grade 2\u20135 radiation pneumonitis after stereotactic radiation therapy for lung tumors","volume":"2","author":"Yamashita","year":"2007","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijrobp.2010.08.056","article-title":"A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy","volume":"82","author":"Barriger","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2013.10.011","article-title":"Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs","volume":"109","author":"Bongers","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0060","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.ijrobp.2012.01.018","article-title":"Dose\u2013volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer","volume":"83","author":"Matsuo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0065","doi-asserted-by":"crossref","first-page":"20160560","DOI":"10.1259\/bjr.20160560","article-title":"Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer","volume":"89","author":"Nakamura","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2020.12.015_b0070","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.ijrobp.2016.04.016","article-title":"Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable stage I non-small cell lung cancer: a systemic review and pooled analysis","volume":"95","author":"Bi","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0075","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1002\/cncr.29640","article-title":"Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National Cancer Data Base analysis","volume":"121","author":"Nanda","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.12.015_b0080","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ijrobp.2007.04.077","article-title":"A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data","volume":"69","author":"Bradley","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijrobp.2005.11.046","article-title":"Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters","volume":"65","author":"Hope","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/107327480801500206","article-title":"The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy","volume":"15","author":"Kong","year":"2008","journal-title":"Cancer Control"},{"key":"10.1016\/j.radonc.2020.12.015_b0095","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0105","unstructured":"Stereotactic Ablative Body Radiation Therapy (SABR): A Resource; SABR uk consortium [Internet]. January, 2014. Available from: http:\/\/www.actionradiotherapy.org\/wp-content\/uploads\/2014\/05\/UKSABRConsortiumGuidellinesv41.pdf."},{"key":"10.1016\/j.radonc.2020.12.015_b0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clon.2015.09.007","article-title":"Stereotactic ablative radiotherapy (SABR) in patients with medically inoperable peripheral early stage lung cancer: outcomes for the first UK SABR cohort","volume":"28","author":"Murray","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2020.12.015_b0115","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. USDEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute. May 28, 2009 (v4.03: June 14, 2010)."},{"key":"10.1016\/j.radonc.2020.12.015_b0120","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/j.prro.2019.01.012","article-title":"Characterization of chest wall toxicity during long-term follow up after thoracic stereotactic body radiation therapy","volume":"9","author":"Chipko","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0125","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-018-1156-1","article-title":"Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer","volume":"13","author":"Dreyer","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.radonc.2016.05.007","article-title":"Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)","volume":"119","author":"Chaudhuri","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0135","doi-asserted-by":"crossref","first-page":"20160508","DOI":"10.1259\/bjr.20160508","article-title":"Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours","volume":"90","author":"Okubo","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2020.12.015_b0140","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.3747\/co.25.4093","article-title":"Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients?","volume":"25","author":"Kasymjanova","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0145","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.prro.2018.09.003","article-title":"Impact of tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors","volume":"9","author":"Parker","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0150","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2013.08.020","article-title":"The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer","volume":"87","author":"Allibhai","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12931-018-0775-2","article-title":"Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung cancer","volume":"19","author":"Torre-Bouscoulet","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.radonc.2020.12.015_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208637","article-title":"Evaluating risk factors of radiation pneumonitis after stereotactic body radiation therapy in lung tumor: meta-analysis of 9 observational studies","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2020.12.015_b0165","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2008.21.5681","article-title":"Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy","volume":"27","author":"Baumann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0170","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/COC.0b013e3180ca7cb1","article-title":"Stereotactic body radiation therapy: a comprehensive review","volume":"30","author":"Chang","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-4-1","article-title":"Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study","volume":"4","author":"Hurkmans","year":"2009","journal-title":"Radiat Oncol (London, England)"},{"key":"10.1016\/j.radonc.2020.12.015_b0180","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2007.10.053","article-title":"Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer","volume":"70","author":"Lagerwaard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0185","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.ijrobp.2008.11.019","article-title":"Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer","volume":"73","author":"Xiao","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0190","article-title":"Organs at risk considerations for thoracic stereotactic body radiation therapy: what is safe for lung parenchyma?","author":"Kong","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.12.015_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.radonc.2010.04.027","article-title":"Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy","volume":"97","author":"Guckenberger","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.12.015_b0200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jrr\/rrt146","article-title":"Outcome and toxicity of stereotactic body radiotherapy with helical tomotherapy for inoperable lung tumor: analysis of Grade 5 radiation pneumonitis","volume":"55","author":"Aibe","year":"2014","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2020.12.015_b0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3857\/roj.2017.00066","article-title":"Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy","volume":"35","author":"Kim","year":"2017","journal-title":"Radiat Oncol J"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402031241X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402031241X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:13:36Z","timestamp":1759122816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402031241X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":41,"alternative-id":["S016781402031241X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.12.015","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) \u2013 An analysis of UK\u2019s largest cohort of lung SABR patients","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}